#ESMO26 | Sacituzumab tirumotecan + pembrolizumab in advanced urothelial cancer (Phase II, n=40): ORR 68% | DCR 88% mPFS11.2 months | mOS NRGrade 3–4 TRAEs: 63% Promising activityr

Martin ZapataLaguado· @zapatalaguadomd · X·2026-10-24 16:55· 20 小时前评分70

正文 · 机器翻译

#ESMO26 | Sacituzumab tirumotecan + pembrolizumab 治疗晚期尿路上皮癌（II期，n=40）：ORR 68% | DCR 88% mPFS 11.2个月 | mOS NR Grade 3–4 TRAEs：63% 无论TROP2/PD-L1表达情况如何，均展现出令人鼓舞的活性 @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily

14 浏览 · 1 赞 · 1 转发 · 0 回复

会议摘要

1259PNCT05642780 NCT05642780 NCT05642780按 Gynaecological cancers 对上

Sacituzumab tirumotecan (Sac-TMT) + pembrolizumab (Pembro) in post-platinum advanced mismatch repair proficient (pMMR) endometrial cancer (EC)

https://esmocongress.esmo.org

35P按 Advanced breast cancer, other 对上

Comparative effectiveness of trastuzumab deruxtecan versus sacituzumab govitecan in HER2-negative metastatic breast cancer: A real-world analysis with propensity score matching

https://esmocongress.esmo.org

4739RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Results From a Phase 2 Study (2870-002/SKB264-II-06)

https://esmocongress.esmo.org

4742O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7

https://esmocongress.esmo.org

来源：Martin ZapataLaguado · x.com